Abingdon Health

Abingdon Health is a publicly-traded, UK-based CDMO specializing in lateral flow immunoassay (LFIA) technology, offering a fully integrated service from biomarker validation to commercial manufacturing. A key strategic achievement is establishing a dual UK/US operational footprint, providing clients with tariff-free domestic production, FDA-ready systems, and compliance with US grant programs. The company's strategy focuses on capturing market share in complex IVD and companion diagnostics by reducing time-to-market and de-risking the development pathway for its partners across multiple sectors.

Integrated lateral flow immunoassay (LFIA) development and manufacturing platform, specializing in complex, quantitative, and multiplexed assay formats for point-of-care diagnostics.

Competes against other specialized lateral flow CDMOs and diversified CDMOs with lateral flow divisions. Differentiates through pure-play LFIA expertise, a fully integrated service model, and a strategic, FDA-ready US manufacturing footprint that provides a unique advantage for North American market access.